From last weeks ann:
The Phase II clinical trial of ATL1103 in acromegaly patients continues on track. Applications for
approval to conduct the clinical trial have been made in the UK, France and Spain. Relevant Ethics
Committee and Regulatory approvals have been received in the UK, the main location for recruiting
patients into the trial. One final step of trial approval in the UK is anticipated by early December,
which would allow patient recruitment to commence before the end of the year, as per previous
guidance.
Back in.
From last weeks ann:The Phase II clinical trial of ATL1103 in...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $64.91M | |||
| Open | High | Low | Value | Volume |
| 7.2¢ | 7.4¢ | 7.0¢ | $17.78K | 246.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13800 | 7.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.4¢ | 63495 | 1 |
View Market Depth
| Last trade - 15.22pm 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.4¢ |
Change
0.000 ( 2.78 %) |
||||
| Open | High | Low | Volume | ||
| 7.0¢ | 7.4¢ | 7.0¢ | 44500 | ||
| Last updated 14.24pm 27/05/2024 ? | |||||
| PER (ASX) Chart |